A Phase 2 interventional study of Drug: GSK2251052 and Meropenem in Infections, Intestinal, sponsored by GlaxoSmithKline. Terminated at 31 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-29.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Intraabdominal Infections with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Intraabdominal Infections · United States.
Among the 29 studies in Intraabdominal Infections with a site in United States, this one is the 22nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2011, is one of 9 in phase 2, and was the 7th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →3 of the 29 studies in Intraabdominal Infections with a site in United States are open now. Recruiting first, the newest first:
True Bearing Diagnostics, Inc. · Sites in United States
Ages 7+ · Healthy volunteers
Tetraphase Pharmaceuticals, Inc · Sites in United States
Ages 8–17
Washington University School of Medicine · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 10 · Phase 4 1
First in 2007; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 24 interventional studies, 1,000 across the 5 observational. Of the 23 that completed or were terminated, 19 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 29 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 1 study filed under Intraabdominal Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Intraabdominal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579312True Bearing Diagnostics, Inc.Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Intraabdominal Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the safety, efficacy and pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cIAI.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
This study's enrollment of 15 is below the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Browse Intraabdominal Infections studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Intraabdominal Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
N.B. Females of non-childbearing or may be enrolled. It is not to enrol females of childbearing potential; however, females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:
A subject enrolled as a failure of a previous antibacterial treatment regimen must:
Show lack of improvement or worsening in signs and symptoms of infection, including continued or worsening peritoneal findings Require additional surgical intervention which must be performed within 24 hours of first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis AND/OR Be post-op and have required surgery within 24 hours prior to first dose of study medication with no more than one pre-surgical dose of an antibiotic given for pre-operative prophylaxis.
Have a culture positive for a Gram-negative pathogen (from an intra-abdominal site) N.B. Such subjects may be enrolled before the results of the culture are known but if the culture is negative, the subject must be removed from study drug therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
q12h administered via IV infusion, plus saline placebo
Drug: Drug: GSK2251052 · Other: Placebo
q12h administered via IV infusion, plus saline placebo
Drug: Drug: GSK2251052 · Other: Placebo
q8h administered via IV infusion, plus saline placebo
Drug: Meropenem · Other: Placebo
Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
Also known as: Merrem ®, Meronem
saline placebo
Number of Participants With Any Adverse Event
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE included AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition
Time frame: Up to Day 42
Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration
Vital parameters including systolic and diastolic blood pressure, heart rate, respiration rate, and temperature were recorded. The number of participants with potentially clinically concern value of any vital parameter at any visit were reported.
Time frame: Up to Day 42
Number of Participants With Normal and Abnormal ECG Findings
12-lead ECGs was obtained during the study using an ECG machine and performed with the participant in a semi-supine position rested in this position for at least 10 minutes beforehand. Measurements deviated substantially from previous readings were repeated immediately. Number of participants with normal and abnormal ECG findings were reported.
Time frame: Up to Day 42
Laboratory Parameters of Interest- Mean Hemoglobin Over the Period of Study Duration
Absolute mean hemoglobin values recorded over the period of duration were reported.
Time frame: Up to Day 42
Laboratory Parameters of Interest- Mean Reticulocytes Over the Period of Study Duration
Absolute mean reticulocytes values recorded over the period of duration were reported.
Time frame: Up to 42 days
Mean Change From Baseline in Hemoglobin for Partcipants With Significant Hemoglobin Drop
Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported.
Time frame: Baseline (Day 1) and up to Day 42
Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Intent to Treat (MITT) Population
Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.
Time frame: Day 5 to 9 post IV therapy
Number of Participants With Clinical Response at Test of Cure Visit (5-9 Days Post-therapy) in Microbiological Evaluable Population.
Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.
Time frame: Day 5 to 9 post IV therapy
Number of Participants With Microbiological Response in MITT Population
Microbiological Response at End of IV Therapy was assessed as Microbiological Success (MS) or Microbiological Failure (MF). MS was categorized as microbiological eradication (ME) and presumed microbiological eradication (PME). MF was categorized as microbiological persistence (MP), presumed microbiological persistence (PMP), unable to determine, new infection and colonization. Number of participants with microbiological response in MITT population were reported.
Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Number of Participants With Microbiological Response in Microbiological Evaluable Population
Microbiological Response at End of IV Therapy was assessed as MS or MF. MS was categorized as ME and PME. MF was categorized as MP and PMP, unable to determine, new infection and colonization. Number of participants with microbiological response in microbiological evaluable population were reported.
Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Number of Participants With Clinical Response in Microbiological Evaluable Population
Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.
Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Number of Participants With Clinical Response in MITT Population
Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.
Time frame: End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)
Number of Participants With Therapeutic Response in Microbiological Evaluable Population
Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.
Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Number of Participants With Therapeutic Response in MITT Population
Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.
Time frame: End of IV therapy (0-24 hours post-therapy); Test of cure (5-9 days post-therapy); Late Follow-up (21-28 days post-therapy)
Maximum Plasma Concentration (Cmax) of GSK2251052
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for pharmacokinetics (PK) analysis was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Area Under the Concentration Time Curve (AUC) of GSK2251052
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Time to Cmax (Tmax) of GSK2251052
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Cmax of GSK2251052 Using Non-intensive PK Sampling
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
AUC of GSK2251052 Using Non-intensive PK Sampling
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Tmax of GSK2251052 Using Non-intensive PK Sampling
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose
Cmax of GSK2251052 Using Intensive PK Sampling
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
AUC of GSK2251052 Using Intensive PK Sampling
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
Tmax of GSK2251052 Using Intensive PK Sampling
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
Time frame: Day 5: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose
The study was conducted at five centers in four countries (United Stated of America, Spain, France and Russia) between 03-October-2011 and 05-March-2012.
| Milestone | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1.0 g |
|---|---|---|---|
| Started | 5 | 4 | 5 |
| Completed | 5 | 3 | 5 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE included AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Any AE | 5 | 4 | 3 |
| Any SAE | 2 | 3 | 0 |
Vital parameters including systolic and diastolic blood pressure, heart rate, respiration rate, and temperature were recorded. The number of participants with potentially clinically concern value of any vital parameter at any visit were reported.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Number of Participants With Clinically Significant Trends in Vital Signs Over the Period of Study Duration | 0 | 0 | 0 |
12-lead ECGs was obtained during the study using an ECG machine and performed with the participant in a semi-supine position rested in this position for at least 10 minutes beforehand. Measurements deviated substantially from previous readings were repeated immediately. Number of participants with normal and abnormal ECG findings were reported.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Baseline, Pre-dose 1, Normal | 4 | 4 | 4 |
| Baseline, Pre-dose 1, Unable to evaluate | 0 | 0 | 1 |
| Baseline, Pre-dose 1, Abnormal | 1 | 0 | 0 |
| Baseline, Pre-dose 2, Normal | 4 | 4 | 5 |
| Baseline, Pre-dose 2, Abnormal | 1 | 0 | 0 |
| Baseline, Pre-dose 3, Normal | 4 | 4 | 5 |
| Baseline, Pre-dose 3, Abnormal | 1 | 0 | 0 |
| Baseline, Post-dose , Normal | 4 | 3 | 4 |
| Baseline, Post-dose , Abnormal | 1 | 1 | 1 |
| On IV Therapy (Day 4), Pre-dose, Normal | 4 | 4 | 5 |
| On IV Therapy (Day 4), Pre-dose, Abnormal | 1 | 0 | 0 |
| On IV Therapy (Day 4), Post-dose, Normal | 5 | 4 | 5 |
| Early Follow-up | 5 | 3 | 5 |
Absolute mean hemoglobin values recorded over the period of duration were reported.
| Gram per Litre | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Baseline (Day 1) | 142.2 ± 8.76 | 121.5 ± 12.23 | 125.0 ± 14.85 |
| On IV Therapy (Day 3) | 134.4 ± 13.61 | 112.3 ± 16.30 | 137.3 ± 19.64 |
| On IV Therapy (Day 5) | 127.2 ± 14.79 | 120.7 ± 11.02 | 131.0 ± 18.63 |
| On IV Therapy (Day 8) | 148.0 ± NA | 132.0 ± NA | 143.0 ± NA |
| On IV Therapy (Day 11) | 97.0 ± NA | — | — |
| End Of IV Therapy | 126.2 ± 23.35 | 123.8 ± 9.88 | 130.8 ± 20.22 |
| Haematology Safety | 131.4 ± 15.21 | 118.0 ± 9.93 | 138.6 ± 14.72 |
| Test of cure | 131.0 ± 25.26 | 116.0 ± 5.77 | 138.2 ± 11.52 |
| Early Follow up | 125.5 ± 31.16 | 121.5 ± 3.54 | 138.5 ± 10.54 |
| Late Follow up | 133.2 ± 19.38 | 126.5 ± 0.71 | 146.8 ± 17.25 |
Absolute mean reticulocytes values recorded over the period of duration were reported.
| Trillion cells per Litre | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Baseline (Day 1) | 0.0589 ± 0.01839 | 0.0573 ± 0.00761 | 0.0810 ± 0.02547 |
| On IV Therapy (Day 3) | 0.0487 ± 0.01874 | 0.0638 ± 0.03074 | 0.0725 ± 0.02418 |
| On IV Therapy (Day 5) | 0.0580 ± 0.02377 | 0.0480 ± 0.00515 | 0.0870 ± 0.02888 |
| On IV Therapy (Day 8) | 0.0077 ± NA | 0.0444 ± NA | 0.0650 ± NA |
| On IV Therapy (Day 11) | 0.0335 ± NA | — | — |
| End Of IV Therapy | 0.0564 ± 0.02919 | 0.0602 ± 0.01899 | 0.0872 ± 0.02792 |
| Haematology Safety | 0.0640 ± 0.02406 | 0.0478 ± 0.01937 | 0.0815 ± 0.03405 |
| Test Of Cure | 0.0959 ± 0.01260 | 0.0860 ± 0.01764 | 0.0846 ± 0.01270 |
| Early Follow up | 0.0842 ± 0.02559 | 0.0769 ± 0.00537 | 0.0796 ± 0.02874 |
| Late Follow up | 0.1046 ± 0.02945 | 0.0870 ± 0.01018 | 0.0828 ± 0.01431 |
Participants in whom the hemoglobin level dropped by more than 30% from Baseline that was not attributable to acute blood loss were recorded and immediately withdrawn from study treatment. Baseline assessments were recorded on Visit 1 (Day 1) and used as Baseline values. The change from Baseline was calculated by subtracting the Baseline values from Day 42 values. If either the Baseline or post-randomization value was missing, the change from Baseline was set to missing. The mean change from Baseline in hemoglobin for participants with significant hemoglobin drop were reported.
| grams/L | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| On IV Therapy, Day 3 | -7.8 ± 18.07 | -13.3 ± 8.62 | 0.0 ± 9.90 |
| On IV Therapy, Day 5 | -15.0 ± 18.88 | 1.5 ± 3.54 | -1.7 ± 8.62 |
| On IV Therapy, Day 8 | 3.0 ± NA | -6.0 ± NA | — |
| On IV Therapy, Day 11 | -58.0 ± NA | — | — |
| End of IV Therapy | -16.0 ± 28.88 | -0.7 ± 3.79 | -2.3 ± 3.79 |
| Hematology Safety | -10.8 ± 22.48 | -8.3 ± 13.80 | 10.0 ± 8.72 |
| Test for Cure | -13.3 ± 32.09 | -8.7 ± 15.95 | 11.0 ± 10.58 |
| Early Follow-up | -16.5 ± 39.31 | 6.0 ± 5.66 | 1.5 ± 7.78 |
| Late Follow-up | -9.0 ± 25.82 | 11.0 ± 9.90 | 20.0 ± 2.65 |
Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Test of Cure Clinical Success | 3 | 1 | 4 |
| Test of Cure Clinical Failure | 1 | 1 | 0 |
Test of cure-clinical success was resolution of signs and symptoms of complicated intra-abdominal infection (cIAI) for participants who were clinical successes at the end of IV therapy visit with no new symptoms recorded that were not present at Baseline and no use of additional antibiotic therapy for cIAI. Test of cure-clinical failure was persistence of signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or new signs and symptoms recorded that were not present at a previous visit, or receipt of additional or alternate antibiotic therapy for cIAI or participant had died. Test of cure- unable to determine was refusal to consent to a clinical examination, lost to follow-up. Participants who were 'unable to determine' at End of IV therapy were considered 'unable to determine' Test of cure Visit as well. Due to early termination of the study, a Bayesian approach for informal hypothesis testing was not performed.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Test of Cure Clinical Success | 3 | 1 | 4 |
| End of IV Clinical Failure | 1 | 1 | 0 |
Microbiological Response at End of IV Therapy was assessed as Microbiological Success (MS) or Microbiological Failure (MF). MS was categorized as microbiological eradication (ME) and presumed microbiological eradication (PME). MF was categorized as microbiological persistence (MP), presumed microbiological persistence (PMP), unable to determine, new infection and colonization. Number of participants with microbiological response in MITT population were reported.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, MS, PME | 3 | 1 | 4 |
| End of IV Therapy, MF, MP | 0 | 1 | 0 |
| End of IV Therapy, MF, PMP | 1 | 0 | 0 |
| Test of Cure, MS, PME | 3 | 1 | 4 |
| Test of Cure, MF, PMP | 1 | 1 | 0 |
| Late follow-up, MS, PME | 3 | 1 | 4 |
| Late follow-up, MF, PMP | 1 | 1 | 0 |
Microbiological Response at End of IV Therapy was assessed as MS or MF. MS was categorized as ME and PME. MF was categorized as MP and PMP, unable to determine, new infection and colonization. Number of participants with microbiological response in microbiological evaluable population were reported.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, MS, PME | 3 | 1 | 4 |
| End of IV Therapy, MF, MP | 0 | 1 | 0 |
| End of IV Therapy, MF, PMP | 1 | 0 | 0 |
| Test of Cure, MS, PME | 3 | 1 | 4 |
| Test of Cure, MF, PMP | 1 | 1 | 0 |
| Late follow-up, MS, PME | 3 | 1 | 4 |
| Late follow-up, MF, PMP | 1 | 0 | 0 |
Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, Clinical Success | 3 | 1 | 4 |
| End of IV Therapy, Clinical Failure | 1 | 1 | 0 |
| Late follow-up, Follow-up Clinical Success | 3 | 1 | 4 |
| Late follow-up, End of IV Clinical Failure | 1 | 0 | 0 |
Clinical success was defined as resolution or improvement of Baseline signs and symptoms of cIAI, including white blood cell count within normal limits, participant was afebrile and peritoneal findings consistent with cIAI were no longer present with no new symptoms present that were not present at Baseline and no use of additional or alternate antibiotic therapy. Clinical failure was defined as (1) Lack of improvement or worsening in one or more signs and symptoms of cIAI recorded at Baseline, or reappearance of signs and symptoms that had previously resolved, or (2) signs and symptoms recorded that were not present at Baseline, or (3) receipt of additional or alternate antibiotic therapy for cIAI or (4) participant had died, or (5) participant had an adverse event leading to study drug discontinuation and the participant required additional or alternative antibacterial therapy for the current cIAI.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, Clinical Success, | 3 | 1 | 4 |
| End of IV Therapy, Clinical Failure | 1 | 1 | 0 |
| Late follow-up, Follow-up Clinical Success | 3 | 1 | 4 |
| Late follow-up, End of IV Clinical Failure | 1 | 1 | 0 |
Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, Therapeutic Success | 3 | 1 | 4 |
| End of IV Therapy, Therapeutic Failure | 1 | 1 | 0 |
| Test of Cure, Therapeutic Success | 3 | 1 | 4 |
| Test of Cure, Therapeutic Failure | 1 | 1 | 0 |
| Late Follow-up, Therapeutic Success | 3 | 1 | 4 |
| Late Follow-up, Therapeutic Failure | 1 | 1 | 0 |
Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who had been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response. Therapeutic response was determined programmatically.
| Participants | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| End of IV Therapy, Therapeutic Success | 3 | 1 | 4 |
| End of IV Therapy, Therapeutic Failure | 1 | 1 | 0 |
| Test of Cure, Therapeutic Success | 3 | 1 | 4 |
| Test of Cure, Therapeutic Failure | 1 | 1 | 0 |
| Late Follow-up, Therapeutic Success | 3 | 1 | 4 |
| Late Follow-up, Therapeutic Failure | 1 | 1 | 0 |
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for pharmacokinetics (PK) analysis was not collected.
No measurements were reported for this outcome.
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Cmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
AUC was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Tmax was planned to be determined. A nonlinear mixed effects model as implemented in the program NONMEM was planned to be used to analyze plasma concentration data. However, data for PK analysis was not collected.
No measurements were reported for this outcome.
Collected over AEs were reported up to Late Follow-up visit (Day 42). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2251052 750 mg | 0/5 (0%) | 2/5 (40%) | 4/5 (80%) |
| GSK2251052 1500 mg | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Meropenem 1g | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Event | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| Abdominal abscessInfections and infestations | 0/5 | 2/4 | 0/5 |
| Blood creatinine increasedInvestigations | 0/5 | 1/4 | 0/5 |
| Bile duct stoneHepatobiliary disorders | 0/5 | 1/4 | 0/5 |
| Pelvic abscessInfections and infestations | 1/5 | 0/4 | 0/5 |
| Haemoglobin decreasedInvestigations | 1/5 | 0/4 | 0/5 |
| Pancreatitis acuteGastrointestinal disorders | 1/5 | 0/4 | 0/5 |
| Event | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1g |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/5 | 2/4 | 1/5 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 1/4 | 1/5 |
| DyspepsiaGastrointestinal disorders | 0/5 | 1/4 | 0/5 |
| Infusion site painGeneral disorders | 0/5 | 1/4 | 0/5 |
| Blood creatinine increasedInvestigations | 0/5 | 1/4 | 0/5 |
| Electrolyte imbalanceMetabolism and nutrition disorders | 1/5 | 1/4 | 0/5 |
| HypokalaemiaMetabolism and nutrition disorders | 0/5 | 1/4 | 0/5 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/5 | 1/4 | 0/5 |
| DizzinessNervous system disorders | 0/5 | 1/4 | 0/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/5 | 1/4 | 0/5 |
| Age, Continuous(Years) | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1 g | Total |
|---|---|---|---|---|
| Mean | 34.0 ± 15.05 | 41.3 ± 13.65 | 34.6 ± 10.31 | 36.3 ± 12.49 |
| Sex: Female, Male(Participants) | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1 g | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 1 | 3 |
| Male | 4 | 3 | 4 | 11 |
| Race/Ethnicity, Customized(Participants) | GSK2251052 750 mg | GSK2251052 1500 mg | Meropenem 1 g | Total |
|---|---|---|---|---|
| African American/African Heritage | 1 | 0 | 1 | 2 |
| Asian - Central/South Asian Heritage | 0 | 0 | 1 | 1 |
| Asian - East Asian Heritage | 0 | 1 | 0 | 1 |
| White - White/Caucasian/European | 4 | 3 | 3 | 10 |
Ran from Oct 2011 to primary completion in Mar 2012, 5 months.
Results were first posted in Nov 2017, 5 years 8 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epetraborole